Last reviewed · How we verify
Triamcinolone or Betamethasone
At a glance
| Generic name | Triamcinolone or Betamethasone |
|---|---|
| Also known as | Particulate Steroid |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation (PHASE2, PHASE3)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- MRI and Clinical Predictive Factors of the Response to Arthrographic Distension in Severe Capsulitis
- Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions (PHASE4)
- Periodontal Initial Treatment Combined With Glucocorticoid Therapy for Erosive Oral Lichen Planus (NA)
- Predicting Response to Interventional Pain Management Techniques in Chronic Low Back Pain in a Prospective Cohort.
- Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone or Betamethasone CI brief — competitive landscape report
- Triamcinolone or Betamethasone updates RSS · CI watch RSS
- Stanford University portfolio CI